標題: | A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity |
作者: | Tseng, Feng-Jen Liu, Yen-Ku Chung, Yo-Shong Lin, Yu-Ling Chen, Chia-Hung Wang, Wan-Yi Chen, Yu-Cheng Tsai, Nu-Man Cheng, Tian-Lu Pan, Ru-Yu Hu, Tsung-Ming Lee, Ru-Ping Liao, Kuang-Wen 生物科技學系 分子醫學與生物工程研究所 Department of Biological Science and Technology Institute of Molecular Medicine and Bioengineering |
關鍵字: | Vascular endothelial growth factor;Receptor binding domain of VEGF-A;Immunoglobulin;Fusion protein;Human umbilical vein endothelial cells |
公開日期: | 1-五月-2011 |
摘要: | Vascular endothelial growth factor (VEGF) promotes the growth of solid tumor mainly via VEGF receptor-1 and receptor-2, which are expressed preferentially in proliferating endothelial cells. Therefore, a strategy for simultaneous blockage of both VEGF receptors may have a useful therapeutic effect in tumor growth. In this study, we utilized a fusion protein which is composed of receptor binding domain of VEGF-A (RBDV) and the constant region fragment (Fc) of a human immunoglobulin G1 (IgG1), to interfere with the growth of human umbilical vein endothelial cells (HUVECs) via VEGF receptors. The results showed that RBDV-IgG1 Fc was able to bind with both VEGF receptor-1 and receptor-2. In addition, RBDV-IgG1 Fc could decrease VEGF-induced proliferation and tube formation among HUVECs. Moreover, the cytotoxic test showed RBDV-IgG1 Fc could also enhance the cytotoxic activity of human natural killing cells. The data are suggesting that the fusion protein, RBDV-IgG1 Fc, may have potential as an angiogenesis antagonist for future tumor therapy. |
URI: | http://dx.doi.org/10.1007/s10616-011-9340-2 http://hdl.handle.net/11536/8959 |
ISSN: | 0920-9069 |
DOI: | 10.1007/s10616-011-9340-2 |
期刊: | CYTOTECHNOLOGY |
Volume: | 63 |
Issue: | 3 |
起始頁: | 285 |
結束頁: | 293 |
顯示於類別: | 期刊論文 |